Rapid Review Quiz: Long COVID

Michael Stuart Bronze, MD


March 22, 2022

A recent study found that discontinuation of immunosuppressive therapies during COVID-19 in patients with ulcerative colitis (UC) was independently associated with long-term effects of COVID-19 (odds ratio = 1.50 [95% CI, 1.07-10.22], P = .01). Patients with Crohn's disease (CD) who were hospitalized for acute COVID-19 were nearly three times more likely to report persistent symptoms 12 weeks after acute infection.

Among patients with IBD, fatigue was the most common long COVID symptom (37% of patients with CD, 36% of patients with UC). Anosmia and ageusia were also common long COVID symptoms, with anosmia reported by 29% and 27% of patients with CD and UC, respectively, and ageusia reported by 28% and 19% of patients with CD and UC, respectively.

Along with IBD disease activity, older age, and presence of comorbidities, smoking was not associated with a significantly elevated risk for long COVID.

Learn more about IBD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.